Corticosteroid injections for carpal tunnel syndrome: Long-term follow-up in a population-based cohort

Stefanie Evers, Andrew J. Bryan, Thomas L. Sanders, Tina Gunderson, Russell Gelfman, Peter C Amadio

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Corticosteroid injection is a recommended treatment option for carpal tunnel syndrome, before considering surgery. Nevertheless, injections remain controversial because there is strong evidence of only short-term benefits. This study aimed to determine the reintervention rate and to identify prognostic indicators for subsequent treatment after corticosteroid injection for carpal tunnel syndrome. Methods: This study evaluated residents of Olmsted County treated with a corticosteroid injection for carpal tunnel syndrome between 2001 and 2010. Treatment failure was the primary outcome of interest. Two definitions for failure were examined: (1) the patient receiving subsequent procedural intervention and (2) the patient undergoing carpal tunnel release. Survival was estimated using Kaplan-Meier methods, and association of covariates with increased failure was modeled using Cox proportional hazards regression. Results: The study included 774 affected hands in 595 patients. The median follow-up period was 7.4 years. Reintervention was performed in 68 percent of cases, of which 63 percent resulted in eventual surgery. Injectate volume was significant for the outcome of any retreatment [hazard ratio, 0.879 (95 percent CI, 0.804 to 0.96)] and surgery [hazard ratio, 0.906 (95 percent CI, 0.827 to 0.99)]. Rheumatoid arthritis was also significant in both models, with a hazard ratio of 0.627 (95 percent CI, 0.404 to 0.97) for any retreatment and 0.493 (95 percent CI, 0.292 to 0.83) for surgery. Conclusions: In this cohort, 32 percent of patients did not receive subsequent treatment after a single injection, which indicates that there is a therapeutic role for corticosteroid injections in treating carpal tunnel syndrome. Further research is necessary to identify those patients who will benefit from an injection, to provide more individually tailored treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

Original languageEnglish (US)
Pages (from-to)338-347
Number of pages10
JournalPlastic and Reconstructive Surgery
Volume140
Issue number2
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Carpal Tunnel Syndrome
Adrenal Cortex Hormones
Injections
Population
Retreatment
Therapeutics
Wrist
Treatment Failure
Rheumatoid Arthritis
Hand
Survival
Research

ASJC Scopus subject areas

  • Surgery

Cite this

Corticosteroid injections for carpal tunnel syndrome : Long-term follow-up in a population-based cohort. / Evers, Stefanie; Bryan, Andrew J.; Sanders, Thomas L.; Gunderson, Tina; Gelfman, Russell; Amadio, Peter C.

In: Plastic and Reconstructive Surgery, Vol. 140, No. 2, 01.08.2017, p. 338-347.

Research output: Contribution to journalArticle

Evers, Stefanie ; Bryan, Andrew J. ; Sanders, Thomas L. ; Gunderson, Tina ; Gelfman, Russell ; Amadio, Peter C. / Corticosteroid injections for carpal tunnel syndrome : Long-term follow-up in a population-based cohort. In: Plastic and Reconstructive Surgery. 2017 ; Vol. 140, No. 2. pp. 338-347.
@article{0f671d3abaaa4255b55b2f44bd22b505,
title = "Corticosteroid injections for carpal tunnel syndrome: Long-term follow-up in a population-based cohort",
abstract = "Background: Corticosteroid injection is a recommended treatment option for carpal tunnel syndrome, before considering surgery. Nevertheless, injections remain controversial because there is strong evidence of only short-term benefits. This study aimed to determine the reintervention rate and to identify prognostic indicators for subsequent treatment after corticosteroid injection for carpal tunnel syndrome. Methods: This study evaluated residents of Olmsted County treated with a corticosteroid injection for carpal tunnel syndrome between 2001 and 2010. Treatment failure was the primary outcome of interest. Two definitions for failure were examined: (1) the patient receiving subsequent procedural intervention and (2) the patient undergoing carpal tunnel release. Survival was estimated using Kaplan-Meier methods, and association of covariates with increased failure was modeled using Cox proportional hazards regression. Results: The study included 774 affected hands in 595 patients. The median follow-up period was 7.4 years. Reintervention was performed in 68 percent of cases, of which 63 percent resulted in eventual surgery. Injectate volume was significant for the outcome of any retreatment [hazard ratio, 0.879 (95 percent CI, 0.804 to 0.96)] and surgery [hazard ratio, 0.906 (95 percent CI, 0.827 to 0.99)]. Rheumatoid arthritis was also significant in both models, with a hazard ratio of 0.627 (95 percent CI, 0.404 to 0.97) for any retreatment and 0.493 (95 percent CI, 0.292 to 0.83) for surgery. Conclusions: In this cohort, 32 percent of patients did not receive subsequent treatment after a single injection, which indicates that there is a therapeutic role for corticosteroid injections in treating carpal tunnel syndrome. Further research is necessary to identify those patients who will benefit from an injection, to provide more individually tailored treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.",
author = "Stefanie Evers and Bryan, {Andrew J.} and Sanders, {Thomas L.} and Tina Gunderson and Russell Gelfman and Amadio, {Peter C}",
year = "2017",
month = "8",
day = "1",
doi = "10.1097/PRS.0000000000003511",
language = "English (US)",
volume = "140",
pages = "338--347",
journal = "Plastic and Reconstructive Surgery",
issn = "0032-1052",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Corticosteroid injections for carpal tunnel syndrome

T2 - Long-term follow-up in a population-based cohort

AU - Evers, Stefanie

AU - Bryan, Andrew J.

AU - Sanders, Thomas L.

AU - Gunderson, Tina

AU - Gelfman, Russell

AU - Amadio, Peter C

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: Corticosteroid injection is a recommended treatment option for carpal tunnel syndrome, before considering surgery. Nevertheless, injections remain controversial because there is strong evidence of only short-term benefits. This study aimed to determine the reintervention rate and to identify prognostic indicators for subsequent treatment after corticosteroid injection for carpal tunnel syndrome. Methods: This study evaluated residents of Olmsted County treated with a corticosteroid injection for carpal tunnel syndrome between 2001 and 2010. Treatment failure was the primary outcome of interest. Two definitions for failure were examined: (1) the patient receiving subsequent procedural intervention and (2) the patient undergoing carpal tunnel release. Survival was estimated using Kaplan-Meier methods, and association of covariates with increased failure was modeled using Cox proportional hazards regression. Results: The study included 774 affected hands in 595 patients. The median follow-up period was 7.4 years. Reintervention was performed in 68 percent of cases, of which 63 percent resulted in eventual surgery. Injectate volume was significant for the outcome of any retreatment [hazard ratio, 0.879 (95 percent CI, 0.804 to 0.96)] and surgery [hazard ratio, 0.906 (95 percent CI, 0.827 to 0.99)]. Rheumatoid arthritis was also significant in both models, with a hazard ratio of 0.627 (95 percent CI, 0.404 to 0.97) for any retreatment and 0.493 (95 percent CI, 0.292 to 0.83) for surgery. Conclusions: In this cohort, 32 percent of patients did not receive subsequent treatment after a single injection, which indicates that there is a therapeutic role for corticosteroid injections in treating carpal tunnel syndrome. Further research is necessary to identify those patients who will benefit from an injection, to provide more individually tailored treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

AB - Background: Corticosteroid injection is a recommended treatment option for carpal tunnel syndrome, before considering surgery. Nevertheless, injections remain controversial because there is strong evidence of only short-term benefits. This study aimed to determine the reintervention rate and to identify prognostic indicators for subsequent treatment after corticosteroid injection for carpal tunnel syndrome. Methods: This study evaluated residents of Olmsted County treated with a corticosteroid injection for carpal tunnel syndrome between 2001 and 2010. Treatment failure was the primary outcome of interest. Two definitions for failure were examined: (1) the patient receiving subsequent procedural intervention and (2) the patient undergoing carpal tunnel release. Survival was estimated using Kaplan-Meier methods, and association of covariates with increased failure was modeled using Cox proportional hazards regression. Results: The study included 774 affected hands in 595 patients. The median follow-up period was 7.4 years. Reintervention was performed in 68 percent of cases, of which 63 percent resulted in eventual surgery. Injectate volume was significant for the outcome of any retreatment [hazard ratio, 0.879 (95 percent CI, 0.804 to 0.96)] and surgery [hazard ratio, 0.906 (95 percent CI, 0.827 to 0.99)]. Rheumatoid arthritis was also significant in both models, with a hazard ratio of 0.627 (95 percent CI, 0.404 to 0.97) for any retreatment and 0.493 (95 percent CI, 0.292 to 0.83) for surgery. Conclusions: In this cohort, 32 percent of patients did not receive subsequent treatment after a single injection, which indicates that there is a therapeutic role for corticosteroid injections in treating carpal tunnel syndrome. Further research is necessary to identify those patients who will benefit from an injection, to provide more individually tailored treatment. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, III.

UR - http://www.scopus.com/inward/record.url?scp=85026290832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026290832&partnerID=8YFLogxK

U2 - 10.1097/PRS.0000000000003511

DO - 10.1097/PRS.0000000000003511

M3 - Article

C2 - 28746281

AN - SCOPUS:85026290832

VL - 140

SP - 338

EP - 347

JO - Plastic and Reconstructive Surgery

JF - Plastic and Reconstructive Surgery

SN - 0032-1052

IS - 2

ER -